|
|
|
|
|
Highlights from the 2022 American Society of Clinical Oncology Annual Meeting |
|
|
|
|
| Poster Session: Genitourinary Cancer--Prostate Cancer |
|
| Association of PSA Response and Overall Survival in Patients with mHSPC from the Phase 3 ARASENS Trial |
| Fred Saad, MD, FRCS |
| The 2022 ASCO annual meeting featured a session on prostate cancer, including a presentation by Dr. Fred Saad discussing the association of PSA response and overall survival in patients with mHSPC from the phase 3 ARASENS trial. The combination of darolutamide + ADT and docetaxel significantly prolonged the time to PSA progression and more patients receiving darolutamide vs placebo achieved undetectable PSA levels, reflecting strong PSA response over time. |
|
|
|
|
|
| Open-Label Study of Androgen Receptor Inhibition With Darolutamide + ADT Versus ADT in Men With mHSPC Using an External Control Arm (ARASEC) |
| Neal Shore, MD, FACS |
| In this presentation, Neal Shore discussed ARASEC, an open-label study of androgen receptor inhibition with darolutamide + ADT versus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC) using an external control arm. ARASEC is a US-based, phase 2, open-label, single-arm study with an external control arm. Eligible patients will have confirmed adenocarcinoma of the prostate, radiologic evidence of metastatic disease by conventional imaging, and Eastern Cooperative Oncology Group performance status (ECOG PS) ≤2. |
|
|
|
|
|
| Phase 3 VERACITY Clinical Study of Sabizabulin in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on an Androgen Receptor Targeting Agent |
| Robert Dreicer, MD, MS, MACP, FASCO |
| Robert Dreicer described the rationale, design, and protocol of the VERACITY trial examining sabizabulin in men with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor targeting agent. Sabizabulin is an exciting first-in-class agent that may add to the armamentarium for the treatment of mCRPC following progression on ARTAs, a disease space which remains an urgent unmet medical need. |
|
|
|
|
|
| Efficacy and Safety of Relugolix in Men with Advanced Prostate Cancer Based on Baseline BMI: A Subgroup Analysis from the Randomized, Phase 3 HERO Study Versus Leuprolide |
| Fred Saad, MD, FRCS |
| Fred Saad discussed a subgroup analysis of the HERO trial assessing the efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer based on baseline body mass index (BMI). In this HERO study subgroup analysis, relugolix demonstrated greater continuous testosterone suppression than leuprolide regardless of baseline BMI. |
|
|
|
|
|
| Piflufolastat F18-PET/CT in Patients With Prostate Cancer: An Analysis of OSPREY (Cohorts A and B) Standardized Uptake Value Results Stratified by PSA and Gleason Score
|
| Michael Gorin, MD
|
| Michael Gorin examined a subgroup analyses of the OSPREY trial of Piflufolastat F18-PET/CT. Piflufolastat F 18-PET/CT uptake was significantly higher in biopsy positive lesions and increased with baseline PSA. Prostate SUVpeak was highest for men with GS 9-10 histology.
|
|
|
|
|
|
|
|
|
|
|
| Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Castration-Sensitive Prostate Cancer: A Pooled Analysis of the STOMP and ORIOLE Trials
|
| Matthew Deek, MD
|
| Mathew Deek described a pooled analysis of the STOMP and ORIOLE trials examining long-term outcomes and genetic predictors of response to metastasis directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC). This pooled analysis of the only two randomized trials in omCSPC demonstrates a long-term benefit to MDT. Further, a HiRi mutational signature appears prognostic for outcomes in omCSPC and those with HiRi might have a relatively larger magnitude of response to MDT. |
|
|
|
|
|
| Circulating Tumour Cells and PSMA PET Correlates in the Phase I PRINCE Trial of 177Lu-PSMA-617 Plus Pembrolizumab for Metastatic Castration Resistant Prostate Cancer |
| Anis Hamid, MBBS |
| Anis Hamid discussed the value of circulating tumor cells (CTCs) and PSMA PET correlates among patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing combination therapy with 177Lu-PSMA-617 plus pembrolizumab. Despite imaging suitability for therapy, CTCs had heterogenous PSMA expression and genomic alterations associated with aggressive disease. Early changes in PSMA+ CTCs and MTV/TLA were associated with outcomes and may aid in determining the clinical activity of LuPSMA-based therapy.. |
|
|
|
|
|
| Alkaline Phosphatase Decline and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in the REASSURE Study |
| Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D |
| At the 2022 American Society of Clinical Oncology Annual Meeting held in Chicago and virtually, the poster session focused on Prostate, Testicular, and Penile cancers on Monday afternoon included a presentation from Dr. Nicholas D. James discussing the prognostic value of alkaline phosphatase (ALP) decline among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study. |
|
|
|
|
|
| Outcome of Patients With PSMA PET/CT Screen Failure by VISION Criteria and Treated With 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis
|
| Masatoshi Hotta, MD, Ph.D.
|
| Masatoshi Hotta discussed the outcomes of theranostic treatment with 177Lu-PSMA, among patients who would be deemed ineligible for therapy according to criteria used for inclusion in the VISION trial. Among patients receiving 177Lu-PSMA, those who do not meet the VISION PET inclusion criteria have significantly worse outcomes. Refinements in patient selection for 177Lu-PSMA are needed to optimize outcomes.
|
|
|
|
|
|
|
|
|
|
|
| PSMA PET Tumor-to-Salivary Glands Ratio (PSG Score) To Predict Response to Lu-177 PSMA Radioligand Therapy: An International Multicenter Retrospective Study |
| Masatoshi Hotta, MD, PhD |
| Masatoshi Hotta also described the value of tumor to salivary gland uptake on PSMA PET in predicting response to Lu-177 PSMA radioligand therapy. PSG score is a predictive biomarker for response to Lu-177 PSMA and has comparable predictive value whether assessed quantitatively (qPSG) or qualitatively (vPSG). |
|
|
|
|
|
| Olaparib Plus Abiraterone As First-Line Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: Pharmacokinetics Data From the PROpel Trial |
| Andrew J. Armstrong MD, MS |
Andrew Armstrong discussed the pharmacokinetics of combined olaparib and abiraterone treatment in men with previously untreated metastatic castration-resistant prostate cancer (mCRPC) treated in the PROpel trial. Combination treatment with olaparib (full monotherapy dose: 300 mg bid) and abiraterone (1000 mg qd) in patients with mCRPC had no clinically significant effect on the PK profiles of either drug. This confirms that there were no relevant PK-based drug-drug interactions between olaparib and abiraterone.
|
|
|
|
|
|
| Association of RB1 Mutational Status With Overall Genomic Landscape in Neuroendocrine Prostate Cancer |
| Petros Grivas, MD, Ph.D. |
| Petros Grivas discussed the association between RB1 mutational status and the genomic landscape of neuroendocrine prostate cancer (NEPC). In patients with NEPC, the presence of RB1 mutation is associated with various genomic alterations that may have clinical relevance. This may be important in informing future trial design. |
|
|
|
|
|
| Reasons for Oncologist and Urologist Treatment Choice in Metastatic Castration-Sensitive Prostate Cancer: A Physician Survey Linked to Patient Chart Reviews in the United States |
| Stephen J. Freedland, MD |
| Stephen Freedland discussed physician reasons for treatment choice among patients with metastatic castrate-sensitive prostate cancer (mCSPC). The authors concluded that physician survey results suggest that perceptions of tolerability and lack of efficacy and financial considerations affect NHT use. Further, in practice, non-guideline-driven PSA reduction goals are associated with low rates of treatment intensification. These results demonstrate the need for further medical education. |
|
|
|
|
|
| Genomic Aberrations Associated with Overall Survival in mCSPC Treated with Apalutamide or Placebo + ADT in TITAN |
| Neeraj Agarwal, MD |
| Neeraj Agarwal discussing genomic aberrations associated with overall survival in mCSPC treated with apalutamide or placebo + ADT in the TITAN trial. TITAN, a phase 3 placebo-controlled study in patients with mCSPC, showed apalutamide + ADT improved radiographic progression-free survival and OS vs placebo + ADT. In this exploratory analysis presented at ASCO 2022, Dr. Agarwal and colleagues reported the relationships between biomarkers and OS in TITAN. |
|
|
|
|
|
| Feasibility of a Novel Wrist-Worn Thermal Device for Management of Vasomotor Symptoms in Patients with Prostate Cancer |
| Alicia K. Morgans, MD, MPH |
| Alicia Morgans discussed the feasibility of a novel wrist-worn thermal device for management of vasomotor symptoms in patients with prostate cancer. Results of this study support the feasibility of the use of the thermal device for management of bothersome hot flashes in prostate cancer survivors. |
|
|
|
|
|
| Clinical Outcomes and Safety of Enzalutamide + ADT in mHSPC in Patients Aged 75 and ≥ 75 Years: ARCHES Post Hoc Analysis |
| Russell Z. Szmulewitz, MD |
| Russell Szmulewitz discussed a post hoc analysis of ARCHES assessing clinical outcomes and safety of enzalutamide + ADT in mHSPC in patients aged < 75 and ≥ 75 years. Enzalutamide + ADT provides clinical benefit and is generally well-tolerated in patients with mHSPC aged ≥75 years, although with some differences in treatment-related adverse events and the need for dose interruption/reduction compared to men aged <75 years of age. These findings support the therapeutic role of enzalutamide, irrespective of age, in men with mHSPC. |
|
|
|
|
|
| Disparities in Delayed Diagnosis, Access to Treatment, and Treatment Delays Among Hispanic Men With Metastatic Prostate Cancer |
| Nishwant Swami, MPH |
| In this presentation, Nishwant Swami described disparities in diagnosis, access to treatment, and treatment delays for Hispanic men with metastatic prostate cancer. The authors demonstrate notable disparities in prostate cancer diagnosis and treatment for Hispanic men, with meaningful differences when stratified by racial subgroup and Hispanic country of origin. |
|
|
|
|
|
| Access to Definitive Treatment and Survival for Intermediate-Risk and High-Risk Prostate Cancer at Hospital Systems Serving Health Disparity Populations |
| Muhieddine Labban, MD |
| Muhieddine Labban discussed disparities in prostate cancer care. Dr. Labban and colleagues sought to examine receipt of guideline-concordant definitive treatment, time to treatment initiation (TTI), and survival for men with prostate cancer receiving care at hospital systems serving health disparity populations (HSDPs). |
|
|
|
|
|
|
